Evotec SE (EVO) Free Cash Flow Growth (3y) (2022 - 2026)
Evotec SE (EVO) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | 39.19% |
| 10 | Evotec SE | 344.50 Mn | 343.98 Mn | - | 26.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.13% |
| Dec 31, 2025 | -79.92% |
| Sep 30, 2025 | 39.06% |
| Jun 30, 2025 | -39.04% |
| Mar 31, 2025 | -28.46% |
| Dec 31, 2024 | -141.33% |
| Sep 30, 2024 | 125.60% |
| Jun 30, 2024 | 24.49% |
| Mar 31, 2024 | -471.35% |
| Dec 31, 2022 | 27.29% |